
ChromaDex Corporation CDXC
Quarterly report 2025-Q3
added 11-04-2025
ChromaDex Corporation Interest Expense 2011-2025 | CDXC
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense ChromaDex Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 3 K | -55 K | 71 K | 847 K | 79 K | 153 K | 333 K | 159 K | - | 34.3 K | 29 K | -32.1 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 847 K | -55 K | 147 K |
Quarterly Interest Expense ChromaDex Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 239 K | - | 188 K | 125 K | 66 K | - | -5 K | -10 K | -8 K | - | 15 K | 12 K | 19 K | - | 19 K | 24 K | 12 K | - | 314 K | 575 K | 35 K | - | 9 K | 48 K | 44 K | - | 45 K | 36 K | 28 K | - | 2.26 K | 145 K | 188 K | - | 182 K | 132 K | 120 K | - | 12.4 K | 12 K | 9.89 K | - | 8.67 K | 8.06 K | 7.79 K | - | 6.86 K | 7.56 K | 8.26 K | - | 7.52 K | 8.21 K | 8.87 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 575 K | -10 K | 67.6 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
AbbVie
ABBV
|
2.81 B | $ 223.01 | -0.99 % | $ 395 B | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
459 K | $ 4.68 | 1.85 % | $ 777 M | ||
|
Aclaris Therapeutics
ACRS
|
2.95 M | $ 3.38 | 3.21 % | $ 261 M | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-807 K | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-20.7 M | - | - | $ 1.01 B | ||
|
Ascendis Pharma A/S
ASND
|
65.5 M | $ 212.3 | 5.5 % | $ 5 B | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.4 | 1.49 % | $ 8.18 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
4.08 M | $ 25.76 | 0.19 % | $ 1.25 B | ||
|
Brickell Biotech
BBI
|
5 K | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
-12.6 M | - | 0.49 % | $ 251 B | ||
|
Biogen
BIIB
|
250 M | $ 173.03 | -2.55 % | $ 25.2 B | ||
|
BioVie
BIVI
|
4.3 M | $ 1.54 | -2.53 % | $ 2.28 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
2.66 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.33 | 2.3 % | $ 14.6 M | ||
|
Arena Pharmaceuticals
ARNA
|
4.16 M | - | -6.81 % | $ 3.04 B | ||
|
Baudax Bio
BXRX
|
1.36 M | - | 0.59 % | $ 63 K | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
Catalyst Biosciences
CBIO
|
1.04 M | $ 15.32 | 5.73 % | $ 1.01 B | ||
|
Axon Enterprise
AXON
|
286 M | $ 586.28 | 3.15 % | $ 44.4 B | ||
|
Cerus Corporation
CERS
|
1.98 M | $ 2.14 | 13.23 % | $ 395 M | ||
|
Checkpoint Therapeutics
CKPT
|
344 K | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-257 K | - | -16.75 % | $ 25.8 M | ||
|
Celldex Therapeutics
CLDX
|
927 K | $ 28.33 | 0.5 % | $ 1.82 M | ||
|
Clovis Oncology
CLVS
|
444 K | - | -7.23 % | $ 13 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 0.29 | -5.01 % | $ 631 M | ||
|
Cortexyme
CRTX
|
-102 K | - | -1.05 % | $ 67.1 M | ||
|
Benitec Biopharma
BNTC
|
-126 K | $ 12.91 | 0.78 % | $ 531 M | ||
|
Cytokinetics, Incorporated
CYTK
|
37.7 M | $ 60.38 | 0.11 % | $ 6.76 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
16.4 M | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-7.26 M | $ 11.55 | 8.86 % | $ 747 M | ||
|
Dynavax Technologies Corporation
DVAX
|
293 K | $ 10.89 | -0.09 % | $ 1.42 B | ||
|
Eloxx Pharmaceuticals
ELOX
|
-1.65 M | - | -5.68 % | $ 8.28 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M |